Dr Reddy’s Launches Second US Vascepa Rival As Supreme Court Rejects Amarin
Appeal Refused In Litigation Involving Reddy’s And First-To-Market Hikma
Dr Reddy’s has shaken up the market for generic Vascepa in the US by launching its own icosapent ethyl capsules to compete with Hikma’s generic and the Amarin brand, hot on the heels of the Supreme Court’s rejection of the originator’s attempt to overturn a Federal Circuit decision invalidating six Vascepa patents.
You may also be interested in...
Hot on the heels of the first US generic Nexavar launch by Viatris, Dr Reddy’s has followed with a second sorafenib rival. The product represents the latest in a string of significant US launches for the Indian company.
Hikma has warned of renewed pressure on generics in the US after a “gradual worsening of the pricing environment” in 2021. However, the company still managed to achieve growth of a tenth in its generics segment last year, on the back of key launches.
In 2021, courts across the US and beyond continued to weigh key patent litigation fights, alongside the thorny issue of induced infringement via label carve outs and controversial charges for generic price fixing.